Last reviewed: June 27, 2026

Last updated: June 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound and Wegovy dominate headlines as FDA-approved weight loss medications, but many patients assume they are interchangeable. In fact, these two injectables contain different active compounds and follow separate dosing protocols, which means their effectiveness and side effect profiles can vary significantly from person to person.

What Is Zepbound and How Does It Work?

Zepbound contains tirzepatide, a dual-action compound that activates both GLP-1 and GIP receptors in the brain and gut. This dual mechanism is thought to produce stronger appetite suppression and metabolic changes than single-receptor medications. Clinical trials showed participants on tirzepatide lost an average of 21% of their body weight over 72 weeks—a result that set a new benchmark in weight loss pharmacotherapy.

Tirzepatide works by slowing gastric emptying (how fast food leaves your stomach), increasing feelings of fullness, and potentially improving how your body handles blood sugar. The medication is injected once weekly under the skin, and doses typically range from 2.5 mg to 15 mg depending on tolerability and response. Because tirzepatide targets two receptor pathways simultaneously, some patients report more pronounced reductions in hunger compared to single-mechanism alternatives.

Understanding Wegovy: Active Ingredient and Mechanism

Wegovy is the brand name for semaglutide when prescribed for weight management, and it activates only the GLP-1 receptor. Semaglutide was originally developed to treat type 2 diabetes and later approved for chronic weight management based on trial data showing an average weight loss of 14–15% over 68 weeks. While effective, this single-receptor approach produces a narrower metabolic footprint than dual-action compounds.

Semaglutide is also a once-weekly injection, with doses escalating from 0.25 mg to 2.4 mg during a 16-week titration phase. Many patients tolerate semaglutide well, though nausea during dose increases is common. The medication has a strong safety record and longer real-world use history than tirzepatide, which may appeal to patients seeking established clinical evidence over newer options.

Zepbound vs Wegovy: Clinical Efficacy and Patient Response

Head-to-head trials directly comparing tirzepatide (Zepbound) to semaglutide (Wegovy) show tirzepatide produces greater weight loss in most populations—approximately 21% versus 14–15% at equivalent time points. However, individual response varies based on genetics, lifestyle, metabolic health, and adherence. Some patients achieve excellent results on semaglutide and prefer its side effect profile, while others respond dramatically only to tirzepatide's dual mechanism.

The reason for this variation lies partly in genetic differences in GLP-1 and GIP receptor function. Patients with specific genetic variants in the GLP1R or GIPR genes may show differential sensitivity to single versus dual-receptor activation. PlexusDx's Precision Peptide Genetic Test examines 14 pathways and 49 peptides to help predict which mechanism—GLP-1 alone, GIP activity, or their combination—may align best with your genetic predispositions, enabling more personalized medication selection before starting treatment.

Cost Comparison: Zepbound, Wegovy, and Compounded Alternatives

Zepbound and Wegovy carry significant brand-name costs, typically ranging from $900 to $1,300 per month without insurance coverage. Most insurance plans now cover these medications for qualifying patients, but out-of-pocket costs, prior authorization delays, and formulary restrictions remain barriers. For uninsured or underinsured patients, the price differential becomes the primary decision factor.

PlexusDx compounded tirzepatide injection starts at $249 per month—a fraction of brand-name Zepbound—while compounded semaglutide injection begins at $149 per month. Both are formulated by licensed 503A compounding pharmacies and require no insurance, membership fees, or flat per-compound pricing increases. PlexusDx also offers oral versions of both medications and dual-compound GLP-Squared formulations for patients exploring combination therapy, all with flat monthly pricing across all dose levels. This accessibility model removes cost as a barrier to evidence-based weight loss treatment.

Side Effects: What to Expect From Each Medication

Both tirzepatide and semaglutide share a common side effect profile rooted in their GLP-1 mechanism: nausea, vomiting, diarrhea, constipation, and decreased appetite are most frequent during dose escalation. These gastrointestinal effects typically resolve within days to weeks as the body acclimates. Tirzepatide carries an additional small risk of pancreatitis and thyroid concerns in preclinical models, though human safety data remains reassuring across thousands of treated patients.

Semaglutide has been used in diabetes care for longer, providing a larger real-world safety database. Some patients report that semaglutide's side effects are milder than tirzepatide's, while others experience the opposite. Individual tolerance is highly variable and linked to genetics, concurrent medications, and gastrointestinal baseline health. Discussing side effect expectations with your healthcare provider and potentially using the Precision Peptide Genetic Test to understand your peptide-pathway sensitivities can help you prepare mentally and manage symptoms proactively.

Which Medication Is Right for You?

Choosing between tirzepatide and semaglutide depends on efficacy goals, genetic factors, side effect tolerance, cost, and individual health history. Tirzepatide offers superior weight loss outcomes on average but may carry higher initial side effect burden. Semaglutide provides a well-established safety profile and may suit patients preferring a gentler introduction or those with a history of pancreatitis concerns.

PlexusDx offers both medications at transparent, affordable pricing with the option to add the Precision Peptide Genetic Test ($99 after your first month) to guide medication selection based on your unique peptide-pathway genetics. This precision approach removes guesswork: rather than trial-and-error across multiple months, you start with the medication most likely to work with your biology. PlexusDx serves all 50 states, requires no insurance, and makes HSA and FSA contributions eligible, ensuring that cost and access barriers do not prevent you from accessing personalized weight loss therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Zepbound the same as Wegovy?

No. Zepbound contains tirzepatide (dual GLP-1 and GIP receptor activation), while Wegovy contains semaglutide (GLP-1 activation only). Both are once-weekly injectables, but tirzepatide typically produces greater weight loss—approximately 21% versus 14–15%—according to clinical trial data.

Which produces faster weight loss: Zepbound or Wegovy?

Tirzepatide (Zepbound) generally shows faster and more substantial weight loss in clinical trials, with participants reaching higher percentages of body weight reduction by week 52. However, individual results vary based on genetics, diet, exercise, and medication adherence, so some patients achieve excellent outcomes on semaglutide.

Can I afford Zepbound or Wegovy without insurance?

Brand-name Zepbound and Wegovy cost $900–$1,300 monthly without insurance. PlexusDx compounded tirzepatide injection starts at $249/month and compounded semaglutide at $149/month, require no insurance, and are HSA/FSA eligible—making personalized weight loss accessible to uninsured patients.

Are compounded versions of these medications safe?

Yes. PlexusDx sources all compounded medications from licensed 503A compounding pharmacies, which operate under strict FDA oversight and quality standards. Compounded tirzepatide and semaglutide contain the same active ingredients as brand versions, formulated to match clinical dosing protocols.

How can I know which medication will work best for me?

The PlexusDx Precision Peptide Genetic Test examines your GLP1R, GIPR, FTO, MC4R, and 10 other genetic variants linked to peptide-pathway response. This genetic insight helps predict whether you'll respond better to tirzepatide's dual mechanism, semaglutide's single pathway, or another personalized approach—enabling smarter treatment selection before starting therapy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves